Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sfunga Therapeutics
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
SF001, a next-generation amphotericin B analog polyene antifungal, has completed a first‑in‑human single‑ascending dose Phase 1 trial and is in a multiple‑ascending dose Phase 1 study; it has FDA Fast Track and QIDP designations for early therapy of presumed invasive fungal disease and treatment of invasive aspergillosis, with preclinical data showing potent antifungal activity and reduced renal toxicity vs amphotericin B.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculePolyene antifungal
- Industry
- Biotech
02
Partnerships
no major pharma co-development/licensing partnerships publicly reported; main financial/strategic backers are Deerfield Management and AMR Action Fund
Beyond the preview
Go deeper on Sfunga Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sfunga Therapeutics.